浏览全部资源
扫码关注微信
1.成都中医药大学 基础医学院,成都 610075
2.四川省第二中医医院,成都 610014
Published:05 October 2023,
Published Online:01 September 2022,
Received:30 April 2022,
扫 描 看 全 文
熊珮宇,钟春,张培旭等.基于AMPK/ULK1自噬通路探讨人参败毒散对溃疡性结肠炎黏膜屏障的干预机制[J].中国实验方剂学杂志,2023,29(19):52-59.
XIONG Peiyu,ZHONG Chun,ZHANG Peixu,et al.Renshen Baidusan Protects Mucosal Barrier in Ulcerative Colitis via AMPK/ULK1 Autophagy Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(19):52-59.
熊珮宇,钟春,张培旭等.基于AMPK/ULK1自噬通路探讨人参败毒散对溃疡性结肠炎黏膜屏障的干预机制[J].中国实验方剂学杂志,2023,29(19):52-59. DOI: 10.13422/j.cnki.syfjx.20222142.
XIONG Peiyu,ZHONG Chun,ZHANG Peixu,et al.Renshen Baidusan Protects Mucosal Barrier in Ulcerative Colitis via AMPK/ULK1 Autophagy Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(19):52-59. DOI: 10.13422/j.cnki.syfjx.20222142.
目的
2
研究人参败毒散调控腺苷酸活化蛋白激酶/Unc-51样激酶1(AMPK/ULK1)自噬通路抑制溃疡性结肠炎小鼠黏膜屏障损伤的作用机制。
方法
2
将60只SD大鼠随机分为6组,分为正常组,模型组,柳氮磺胺吡啶肠溶片组(西药组),人参败毒散高、中、低剂量组。通过2,4,6-三硝基苯磺酸(TNBS)/50%乙醇诱导UC模型,西药组(0.3125 g·kg
-1
)、人参败毒散高、中、低剂量组(31.2、15.6、7.8 g·kg
-1
)灌胃2周后,检测结肠组织病理学改变;实时荧光定量聚合酶链式反应(Real-time PCR)检测腺苷酸活化蛋白(AMPK
α
)mRNA表达水平;蛋白免疫印迹法(Western blot)检测紧密连接蛋白中闭合蛋白(Occludin)、紧密连接蛋白蛋白-2(Claudin-2)、自噬标志蛋白p62、微管相关蛋白1轻链3B(LC3B)及AMPK/ULK1通路磷酸化蛋白p-AMPK、p-ULK1的表达水平。
结果
2
与正常组比较,模型组结肠损伤评分明显上调(
P
<
0.05),AMPK
α
mRNA表达明显下调(
P
<
0.05),p-AMPK、p-ULK1、Occludin蛋白水平及LC3Ⅱ/Ⅰ明显下调(
P
<
0.05),而p62、Claudin-2蛋白水平明显上调(
P
<
0.05);与模型组比较,人参败毒散高、中、低剂量组的结肠损伤评分下降,AMPK
α
mRNA明显上调,p-AMPK、p-ULK1、Occludin蛋白水平及LC3Ⅱ/Ⅰ上升,而p62、Claudin-2蛋白表达下降,以人参败毒散中剂量组干预效应最明显(
P
<
0.05)。
结论
2
人参败毒散可抗肠道黏膜屏障损伤,以人参败毒散中剂量组疗效最佳,其机制可能与激活AMPK/ULK1自噬通路有关,通过加速LC3Ⅰ向LC3Ⅱ转化,促进p62降解,从而改善紧密连接蛋白Occludin、Claudin-2功能,修复肠道机械屏障损伤。
Objective
2
To study the mechanism of Renshen Baidusan in regulating adenylate-activated protein kinase (AMPK)/Unc-51-like kinase 1 (ULK1) autophagy pathway to inhibit mucosal barrier damage in the mouse model of ulcerative colitis (UC).
Method
2
Sixty SD rats were randomized into normal, model, sulfasalazine enteric-coated tablets (0.312 5 g·kg
-1
, western medicine), and high-, medium-, and low-dose (31.2, 15.6, 7.8 g·kg
-1
, respectively) Renshen Baidusan groups. The UC model was induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)/50% ethanol. The drugs were administrated by gavage for 2 weeks, and then the histopathological changes of the colon were examined. Real-time quantitative polymerase chain reaction was conducted to measure the mRNA level of AMP-activated protein kinase subunit alpha (AMPK
α
). Western blot was employed to determine the protein levels of closure protein (Occludin), compact linking protein-2 (Claudin-2), autophagy marker p62, microtubule-associated protein 1 light chain 3B (LC3B), phosphorylated AMPK (p-AMPK), and phosphorylated ULK1 (p-ULK1).
Result
2
Compared with the normal group, the model group showed increased colon injury score (
P
<
0.05), down-regulated mRNA level of AMPK
α
(
P
<
0.05) and protein levels of p-AMPK, p-ULK1, and Occludin, decreased LC3Ⅱ/Ⅰ ratio (
P
<
0.05), and up-regulated protein levels of p62 and Claudin-2 (
P
<
0.05). Compared with the model group, all the doses of Renshen Baidusan lowered the colon injury score, up-regulated the mRNA level of AMPK
α
and the protein levels of p-AMPK, p-ULK1, and Occluding, increased LC3Ⅱ/Ⅰ ratio, and down-regulated the protein levels of p62 and Claudin-2. Moreover, the medium-dose group showed a significant intervention effect (
P
<
0.05).
Conclusion
2
Renshen Baidusan can protect the intestinal mucosal barrier from damage, and the medium dose showed the best efficacy. It may activate the AMPK/ULK1 pathway to accelerate the transformation of LC3Ⅰ to LC3Ⅱ and promote the degradation of p62, so as to improve the function of Occludin and Claudin-2 and repair the mechanical damage of the intestinal barrier.
人参败毒散溃疡性结肠炎腺苷酸活化蛋白激酶/Unc-51样激酶1(AMPK/ULK1)通路自噬肠黏膜屏障
Renshen Baidusanulcerative colitisadenylate-activated protein kinase/Unc-51-like kinase 1(AMPK/ULK1) pathwayautophagyintestinal mucosal barrier
李军祥,陈誩.溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):105-111,120.
吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中国实用内科杂志,2018,38(9):796-813.
何琼,李建栋.炎症性肠病流行病学研究进展[J].实用医学杂志,2019,35(18):2962-2966.
贺冰洁,刘志科,沈鹏,等.2011-2020年宁波市鄞州区炎症性肠病发病的流行病学研究[J].北京大学学报:医学版,2022,54(3):511-519.
甄建华,黄光瑞.溃疡性结肠炎病因和发病机制的现代医学研究进展[J].世界华人消化杂志,2019,27(4):245-251.
SÁNCHEZ DE MEDINA F,ROMERO-CALVO I,MASCARAQUE C,et al.Intestinal inflammation and mucosal barrier function[J].Inflamm Bowel Dis,2014,20(12):2394-2404.
OKUMURA R,TAKEDA K.Roles of intestinal epithelial cells in the maintenance of gut homeostasis[J].Exp Mol Med,2017,49(5):e338.
陈岚,贾波,邓怀涵,等.基于“逆流挽舟”法探索人参败毒散对溃疡性结肠炎模型大鼠胃肠功能的影响及作用机制[J].陕西中医,2019,40(3):283-286.
熊珮宇,陈岚,陈旭,等.基于“逆流挽舟”法探索人参败毒散对溃疡性结肠炎大鼠肠黏膜屏障的干预作用[J].世界科学技术—中医药现代化,2021,23(7):2285-2293.
FOERSTER E G,MUKHERJEE T,CABRAL-FERNANDES L,et al.How autophagy controls the intestinal epithelial barrier[J].Autophagy,2022,18(1):86-103.
LARABI A,BARNICH N,NGUYEN H.New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD[J].Autophagy,2020,16(1):38-51.
ELSHAER D,BEGUN J.The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis[J].Semin Cell Dev Biol,2017,61:51-59.
HOOPER K M,BARLOW P G,STEVENS C,et al.Inflammatory bowel disease drugs: A focus on autophagy[J].J Crohns Colitis,2017,11(1):118-127.
张薇,熊珮宇,刘俊宇,等.经典名方人参败毒散的历史沿革与现代临床应用[J].中国实验方剂学杂志,2023,doi:10.13422/j.cnki.syfjx.20230443http://dx.doi.org/10.13422/j.cnki.syfjx.20230443.
徐叔云,卞如濂,陈修.药理实验方法学[M].3版.北京:人民卫生出版社,2002.
MYERS K J,MURTHY S,FLANIGAN A,et al.Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis[J].J Pharmacol Exp Ther,2003,304(1):411-424.
季强,牛巍巍,张晓岚.溃疡性结肠炎治疗目标的现状与挑战[J].中华消化杂志,2022,42(2):141-144.
ANANTHAKRISHNAN A N.Epidemiology and risk factors for IBD[J].Nat Rev Gastroenterol Hepatol,2015,12(4):205-217.
FUMERY M,SINGH S,DULAI P S,et al.Natural history of adult ulcerative colitis in population-based cohorts:A systematic review[J].Clin Gastroenterol Hepatol,2018,16(3):343-356.e3.
JIANG X L,CUI H F.An analysis of 10218 ulcerative colitis cases in China[J].World J Gastroenterol,2002,8(1):158-161.
喻松仁,张一文,华诗培,等.基于脂肪细胞自噬探讨温胆汤干预肥胖痰湿证炎症状态的作用机制[J].中华中医药学刊,2022,40(1):14-18.
伍振辉,刘凡,曾英坚.自噬与肿瘤免疫逃逸相关性及中药干预研究进展[J].中国实验方剂学杂志,2022,28(11):246-255.
IIDA T,ONODERA K,NAKASE H.Role of autophagy in the pathogenesis of inflammatory bowel disease[J].World J Gastroenterol,2017,23(11):1944-1953.
吴东升,张彧,陈大光,等.自噬在炎症性肠病肠黏膜屏障损伤中的作用[J].胃肠病学,2018,23(12):755-758.
YANG L,LIU C,ZHAO W,et al.Impaired autophagy in intestinal epithelial cells alters gut microbiota and host immune responses[J].Appl Environ Microbiol,2018,doi:10.1128/AEM.00880-18http://dx.doi.org/10.1128/AEM.00880-18.
毕顶念,时明阳,胡倩,等.氧化应激诱导AMPK/ULK1通路激活及溶酶体功能障碍在砷致大鼠肝损伤中的作用[J].环境与职业医学,2021,38(12):1376-1382.
韩宏,刘文洁,陈芳,等.铁皮石斛多糖对缺氧/复氧诱导星形胶质细胞AMPK/ULK1通路相关自噬的影响[J].中国现代应用药学,2021,38(17):2110-2115.
刘不悔,何伟明,万毅刚,等.虫草菌丝抑制自噬相关AMPK/ULK1信号活性改善肾小管上皮细胞衰老的分子机制[J].中国中药杂志,2019,44(6):1258-1265.
张欣欣,高飞,陈素枝,等.益肾通络方对膜性肾病大鼠的肾保护作用及对AMPK/mTOR/ULK1信号通路的影响[J].中国实验方剂学杂志,2021,27(12):57-66.
HARDIE D G,ASHFORD M L.AMPK:Regulating energy balance at the cellular and whole body levels[J].Physiology (Bethesda),2014,29(2):99-107.
CHAN E Y,KIR S,TOOZE S A.siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy[J].J Biol Chem,2007,282(35):25464-25474.
OH S H,CHOI Y B,KIM J H,et al.Quantification of autophagy flux using LC3 ELISA[J].Anal Biochem,2017,530:57-67.
EMANUELE S, LAURICELLA M, D'ANNEO A, et al. p62:Friend or Foe?Evidences for OncoJanus and NeuroJanus roles[J].Int J Mol Sci,2020,21(14):5029.
DUAN J L,YIN J,REN W K,et al.Pyrrolidine dithiocarbamate restores gastric damages and suppressive autophagy induced by hydrogen peroxide[J].Free Radic Res,2015,49(2):210-218.
冯燕海,王凤君.紧密连接蛋白Claudin-2研究进展[J].重庆医学,2018,47(5):697-699.
NIGHOT P K,HU C A,MA T Y.Autophagy enhances intestinal epithelial tight junction barrier function by targeting Claudin-2 protein degradation[J].J Biol Chem,2015,290(11):7234-7246.
PAN H H,ZHOU X X,MA Y Y,et al.Resveratrol alleviates intestinal mucosal barrier dysfunction in dextran sulfate sodium-induced colitis mice by enhancing autophagy[J].World J Gastroenterol,2020,26(33):4945-4959.
陈岚,贾波,邓怀涵.基于“逆流挽舟”法论治溃疡性结肠炎[J].中华中医药杂志,2019,34(2):527-529.
0
Views
18
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution